APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study is a two stage study consisting of a dose escalation phase Ib and a phase II study
which include subjects with previously-treated, advanced pancreatic adenocarcinoma. Dose
Limiting Toxicities (DLTs) and maximum tolerated dose (MTD) of APG1387 in combination with
nab-paclitaxel and gemcitabine will be evaluated in the dose escalation phase Ib. Safety and
efficacy of APG1387 plus gemcitabine and nab-paclitaxel will be evaluated in phase II.